EUVIMEDEUVIMED entdecken
Kommentar

In outpatients with mild to moderate COVID-19, low-dose fluvoxamine did not reduce time to sustained recovery

Jeremy Clark, Steven Y C Tong

Annals of Internal Medicine · 2023

DOI: 10.7326/j23-0025 ↗

Kurz gefasst

Kommentar in der Zeitschrift Annals of Internal Medicine, 2023. Verfasst von Jeremy Clark und 1 weiteren Autor:innen. Beteiligte Einrichtung: Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia (J.C., S.Y.T.). Hauptthemen laut MEDLINE: COVID-19, Fluvoxamine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SOURCE CITATION: McCarthy MW, Naggie S, Boulware DR, et al. Effect of fluvoxamine vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2023;329:296-305. 36633838.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19FluvoxamineHumansCOVID-19 Drug TreatmentDouble-Blind MethodOutpatientsRandomized Controlled Trials as Topic

Substanzen

Fluvoxamine

Autor:innen und Institutionen

  • Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia (J.C., S.Y.T.).

Zitieren

APA

Clark, J., & Tong, S. Y. C. (2023). In outpatients with mild to moderate COVID-19, low-dose fluvoxamine did not reduce time to sustained recovery. Annals of Internal Medicine. https://doi.org/10.7326/j23-0025

Vancouver

Clark J, Tong SYC. In outpatients with mild to moderate COVID-19, low-dose fluvoxamine did not reduce time to sustained recovery. Annals of Internal Medicine. 2023. doi:10.7326/j23-0025

BibTeX
@article{Clark2023,
  author = {Clark, Jeremy and Tong, Steven Y C},
  title = {In outpatients with mild to moderate COVID-19, low-dose fluvoxamine did not reduce time to sustained recovery},
  journal = {Annals of Internal Medicine},
  year = {2023},
  doi = {10.7326/j23-0025}
}
Kostenlos starten →